PG 11047

Drug Profile

PG 11047

Alternative Names: CGC-11047; PG-11047; SL-11047

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellgate
  • Developer EPI Pharmaceuticals; Progen Pharmaceuticals Inc
  • Class Antineoplastics; Polyamines
  • Mechanism of Action Apoptosis stimulants; Cell division modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours
  • Discontinued Age-related macular degeneration; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Monotherapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top